Message #29 From:
Stock News Bot Date: November 6, 2006 05:00:00 AM
CLRI News Clearant Announces Record Direct Distribution of Sterile Implants in October
LOS ANGELES--(BUSINESS WIRE)--Clearant, Inc. (OTCBB:CLRI) today announced that 26 Clearant Process®
Sterile Implant cervical spinal and soft tissue allograft implants were
distributed directly during the month of October. This is a significant
increase, as direct distribution of implants has grown 50 percent from
the monthly average in the third quarter, which was the company’s
first full quarter under the new growth initiative.
Launched in the last few days of June, Clearant’s
direct distribution, which makes Clearant Process®
Sterile Implants directly available to surgeons and clinics, has
resulted in continued growth. In addition to the 26 implants distributed
directly by Clearant to the orthopedic surgeon community, an estimated
400 to 500 additional implants were distributed by Clearant licensees
during the month of October.
“We are highly encouraged by the past month’s
results, demonstrating the growing demand for sterilized implants by
surgeons,” said Clearant Chief Executive
Officer Alain Delongchamp. “We anticipate that
the demand for sterile implants will continue to grow as we reach out to
more surgeons and continue to expand the number of Clearant Process®
product offerings.”
Clearant’s implants are sterilized using the
Clearant Process®, a sterilization technology
that virtually eliminates the risk of infection in bone and soft-tissue
allograft implants while preserving their functional viability.
About Clearant, Inc.
Clearant, Inc. is a leader in pathogen inactivation for biological
products. Clearant has developed the patent-protected Clearant Process,
which substantially reduces all types of bacteria and viruses in
biological products while maintaining the functionality of the
underlying tissue implant or protein. The Company began to distribute
directly to surgeons, hospitals and clinics Clearant Process sterile
implants in June 2006; in addition, Clearant continues to license the
Clearant Process and provides its patented sterilization services to
tissue banks and other biological products manufacturers. As of the end
of 1Q 2006, Clearant had 10 license and service agreements with tissue
banks. To date more than 9,000 patients have been successfully implanted
with Clearant Process sterile implants supplied by one of the Company's
licensed partners. Whereas various competing sterilization methods only
kill specific types of pathogens (such as bacteria or lipid-enveloped
viruses) for specific products, the Clearant Process reduces all types
of pathogens for products across many market segments including tissue
implants, plasma proteins, recombinant products, medical devices and
blood products. Also, the Clearant Process can be applied at various
stages of product processing and/or manufacturing, including in the
final packaging. For more information, please visit www.clearant.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in
this press release are forward looking and made pursuant to the Safe
Harbor provisions of the Private Securities Litigation Reform Act of
1995, in particular statements regarding surgeons strongly recommending
the use of implants with tissue treated by the CLEARANT PROCESS, and the
conclusions from a study by surgeons to build demand for sterilized
tissue.These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many of
which are beyond the company's control, which may cause actual results
to differ materially from stated expectations. These risk factors
include, among others, limited operating history, difficulty in
developing, exploiting and protecting proprietary technologies, results
of additional clinical studies, acceptance and success of our direct
distribution of allografts, efficacy of the technology, intense
competition and substantial regulation in the biotechnology industry,
and additional risks discussed in the company's filings with the SEC,
available on the SEC web site http://www.sec.gov.
